Objective: Superpulsed radiofrequency, a new energy, has been developed and applied in transurethral resection of the prostate (TURP) using a regular cutting loop. The aim of the study was to evaluate the clinical application of superpulsed radiofrequency to reduce bleeding morbidity and to improve patient outcome. The original results of the experimental and clinical study are presented. Methods: From November 1997 to June 1998, 37 patients were submitted to a clinical, nonrandomized study. The age range was 45–81 years. All patients completed the International Prostate Symptom Score (IPSS) and were examined using digital rectal examination, prostate-specific antigen level, transrectal ultrasound, free uroflow, and urodynamic pressure flow study. Hemoglobin was tested before and after surgery. Follow-up was at 3 and 6 months. All operations were performed with a short-acting spinal anesthesia and the resected prostate weight was 18–66 g. Results: 36 patients were treated as 1-day surgery; 1 patient was hospitalized for 1 day. Intraoperative bleeding was very low (hemoglobin tested before and after surgery): the postoperative Hb was <1 g/dl in 34 patients, and Hb = 2 g/dl in 3 patients. Postoperative bleeding was minimal; late bleedings were not observed. Stress incontinence or incontinence were not observed. At 6 months, the patients were asked about any changes in their sexual lives, and no symptoms of impotence were reported. The peak flow rate (PFR) ranged from 4 to 7 ml/s at baseline, with a medium PFR of 5.5 ml/s. At 3 and 6 months the average increase in PFR was 11 and 10 ml/s, respectively, in all patients. Conclusions: As shown by this study, superpulsed radiofrequency is a safe and effective technology. It is superior to high-frequency surgical units and high-frequency coagulating intermittent cutting in terms of whole intraoperative bleeding (hemoglobin tested before and after surgery) and for the impressive impact on minimizing postoperative bleeding. In terms of improvement in urinary flow, the results of TURP with superpulsed radiofrequency at 3 and 6 months are comparable with the average PFR generally reported for TURP performed with high-frequency surgical units. Moreover, superpulsed radiofrequency TURP enhances the gold standard and makes TURP competitive with the other alternative treatments available for benign prostatic hyperplasia. Further studies could better define and extend the application of this new form of energy either in urologic or general surgery.

Keywords:
Radiofrequency superpulsed, Transurethral resection of the prostate
1.
Gordon NS, Hadlow G, Knight E, Mohan P: Transurethral resection of the prostate: Still the gold standard. Aust NZ J Surg 1997;67:354–357.
2.
Haupt G, Pannek J, Benkert S, Heinrich C, Schulze H, Senge T: Transurethral resection of the prostate with microprocessor controlled electrosurgical unit. J Urol 1997;158:497–501.
3.
Kaplan SA, Laor E, Fatal M, Te AE: Transurethral resection of the prostate versus transurethral electrovaporization of the prostate: A blinded, prospective comparative study with 1-year followup. J Urol 1998;159:454–458.
4.
Kunelius P, Häkkinen J, Lukkarinen O: Sexual functions in patients with benign prostatic hyperplasia before and after transurethral resection of the prostate. Urol Res 1998;26:7–9.
5.
Mostafid AH, Harrison NW, Thomas PJ, Fletcher MS: A prospective randomized trial of interstitial radiofrequency therapy versus transurethral resection for the treatment of benign prostatic hyperplasia. Br J Urol 1997;80:116–122.
6.
Nitti VW, Kim Y, Combs AJ: Voiding dysfunction folllowing transurethral resection of the prostate: Symptoms and urodynamic findings. J Urol 1997;157:600–603.
7.
Patel A, Fuchs GJ, Gutierrez Aceves J, Ryan TP: Prostate heating patterns comparing electrosurgical transurethral resection and vaporization: A prospective randomized study. J Urol 1997;157:169–172.
8.
Patel A, Fuchs GJ, Gutierrez Aceves J: A pilot study of energy utilization patterns during different transurethral electrosurgical treatments of the prostate. Urology 1997;50:138–141.
9.
Schatzl G, Madersbacher S, Lang T, Marberger M: The early postoperative morbidity of transurethral resection of the prostate and of 4 minimally invasive treatment alternatives. J Urol 1997;158:105–111.
10.
Soderdahl DW, Knight RW, Hansberry KL: Erectile dysfunction following transurethral resection of the prostate. J Urol 1996;156:1354–1356.
11.
Zwergel U, Wullich B, Lindenmeir U, Rohde V, Zwergel T: Long-term results following transurethral resection of the prostate. Eur Urol 1998;33:476–480.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.